ANTINEOPLASTON AS2-1 FOR MAINTENANCE THERAPY IN LIVER-CANCER

Antineoplaston AS2-1 exhibits cytostatic growth inhibition of human he patocellular carcinoma cells in vitro and showed minimum adverse effec ts in a phase I clinical trial. Liver cancer is difficult to control b ecause of multicentricity and underlying liver disease. We reviewed tw o clinical cases of liver cancer (hepatocellular carcinoma and multipl e liver metastases from colon cancer) in whom we believe antineoplasto n A2-1 was useful as a maintenance therapy after transcatheter arteria l embolization (TAE) and microwave coagulation necrosis (MCN). The two patients have continued to be in good condition for more than two yea rs without limitation of their normal activities. Antineoplaston AS2-1 may be effective and useful as a maintenance agent after TAE and MCN in patients with liver cancer.